Introduction

The Food Standards Agency’s (FSA) move towards formal novel‑food authorisations for edible CBD marks a potential turning point for the UK hospitality sector. If ministers accept the FSA’s draft recommendations launched for consultation on 28 August 2025, those products would become the first fully regulated CBD foods in Great Britain. That regulatory clarity could unlock new product innovation — including no/low‑alcohol CBD beverages aimed at the growing ‘sober‑curious’ market — but it will also bring fresh responsibilities for pubs, bars and retailers.

Where we are: the FSA process and what’s changed

Until recently edible CBD sat in regulatory limbo. The FSA treats CBD used in foods and drinks as a novel food requiring pre‑market authorisation, and until the current applications progressed no CBD novel foods had been approved in the UK. On 28 August 2025 the FSA launched a public consultation on draft recommendations to authorise the first CBD food products as novel foods in Great Britain; if ministers approve these recommendations those products would become the first fully regulated CBD foods in the UK.

Three applications — RP07, RP350 and RP427 — have moved through the FSA’s risk assessment and passed the FSA’s ‘risk management’ phase, advancing toward ministerial decisions in 2025–26. Trade press and legal analysts now expect the first government‑approved CBD foods to reach shelves in 2026, which would allow manufacturers and hospitality operators to reformulate and launch new CBD‑infused beverages.

Market opportunity: why pubs could be interested

The no/low‑alcohol category has grown rapidly in recent years as consumers explore moderation without sacrificing ritual or flavour. Authorised CBD foods could add another dimension: drinks that combine non‑intoxicating botanicals with a clear, regulated CBD content designed for evening occasions or social settings.

For operators seeking quick entry points, finished ingredient formats make pilot launches simpler. For example, an operator might trial a bar‑friendly option using a CBD Drinks Enhancer designed for mixology, or explore paired offerings such as low‑alcohol coffee cocktails using Cannacoffee Original CBD Coffee Pods. For in‑house development, cold‑pressed drops like Wylde Natural Cold‑Pressed Drops 1000mg or high‑purity tinctures such as CBD Living Tincture 4500mg 0‑THC could be used to prototype low‑alcohol serves while keeping THC content minimal.

Regulatory guardrails: safety first

Regulators are prioritising consumer safety. The Advisory Council on the Misuse of Drugs (ACMD) has recommended strict limits on controlled phytocannabinoids — for example, a suggested limit of 50 µg Δ9‑THC per consumption unit — and the FSA consultation references labelling and intake controls. Reported discussions on acceptable daily intake (ADI) include a proposed cap in the region of ~10 mg/day CBD in some coverage, though final figures will be determined through the authorisation process.

Authorisation would not simply allow commercial rollout; it would also create new compliance duties. Manufacturers and operators should expect requirements on permitted product categories, mandatory labelling showing permitted daily intake, clear serving‑size information and documentation to demonstrate product specifications and analytical testing. Enforcement mechanisms and penalties for non‑compliance may follow conventional food‑safety routes.

Licensing, advertising and practical hospitality implications

Even with novel‑food authorisation, CBD drinks in pubs will intersect with multiple regulatory regimes. Licensing authorities may need guidance on whether CBD‑containing drinks impact existing alcohol licensing conditions; local authorities and licensing panels could require risk assessments or conditions for on‑trade service. Advertising and promotion will also be constrained: CBD cannot be promoted as a medicine, and claims must use wellness language only (for example, many people find CBD may support relaxation), in line with ASA/CAP guidance.

Operators must also be mindful of food‑law rules (including HFSS restrictions where relevant), allergen labelling, and age‑restriction policies if products are positioned alongside alcoholic serves. Practical operational issues include staff training on serve sizes and intake limits, storage and traceability of batches, and point‑of‑sale information to help customers make informed choices.

Clinical evidence: what the science says about CBD and alcohol

Scientific interest in CBD as a tool to reduce alcohol use is growing but remains preliminary. Preclinical studies show CBD can reduce alcohol‑motivated behaviours in animal models. Human research from 2020–2025 has produced mixed results: some randomised controlled trials report reductions in cue‑elicited craving or attenuated physiological responses, while other studies show no consistent large effects on drinking volume. In short, evidence suggests potential but is not yet definitive — many researchers call for larger, longer trials before clinical conclusions are drawn.

Accordingly, hospitality messaging should avoid claims that CBD reduces alcohol dependence or treats alcohol‑use disorders; instead use measured wellness language about consumer experience and preference.

THC contamination and workplace testing risks

A key practical risk for hospitality operators is Δ9‑THC contamination. Even trace THC in some CBD products can lead to positive results on sensitive drug tests, affecting staff and customers. The ACMD’s suggested limit of 50 µg per consumption unit is one attempt to address this risk, but operators should demand certificate‑of‑analysis (COA) evidence from suppliers and choose products formulated to minimise controlled cannabinoid content.

Where employers carry out workplace drug testing, clear policies will be needed. Operators may wish to assess suppliers’ batch testing, retain records for traceability and consider whether to permit CBD service in settings with strict zero‑tolerance rules for THC.

Conclusion

The FSA’s 2025–26 novel‑food authorisation pathway could transform the UK market for edible CBD, removing long‑standing regulatory uncertainty and enabling innovation in the no/low‑alcohol sector. For pubs and bars this presents a commercial opportunity to serve differentiated, wellness‑focused beverages for the sober‑curious, but it also imposes new responsibilities: rigorous supplier due diligence, compliance with labelling and intake limits, attention to licensing implications and careful public communication that avoids medical claims. Operators who pair creative product development with robust compliance and staff training will be best placed to navigate this new landscape when the first authorised CBD foods reach the market in 2026.